文献速递炎症性肠病

托法替布与乌帕替尼治疗急性重度溃疡性结肠炎的疗效比较

Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-26

这项多中心回顾性研究纳入2019年1月至2024年6月住院的111例急性重度溃疡性结肠炎成人患者(托法替布60例、乌帕替尼51例),比较两种JAK抑制剂的疗效与安全性。乌帕替尼在治疗开始后第3至7天的应答率高于托法替布(84% vs 54%,P=0.02),但第98天和第182天的应答/缓解率及无结肠切除生存率两组无显著差异,不良事件频率相当。

要点

  • 乌帕替尼第3至7天应答率84% vs 托法替布54%(P=0.02),但第98天和第182天应答/缓解率两组无显著差异。
  • 托法替布与乌帕替尼第98天无结肠切除生存概率分别为79%和75%,第182天分别为80%和78%,生存曲线比较P=0.99。
  • 两种JAK抑制剂用于急性重度溃疡性结肠炎时疗效与安全性特征相似。

核心结论

  • 托法替布与乌帕替尼用于急性重度溃疡性结肠炎治疗时,似乎具有相似的疗效与安全性特征。

研究设计与样本

  • 多中心回顾性研究,纳入2019年1月至2024年6月因急性重度溃疡性结肠炎住院并接受托法替布或乌帕替尼治疗的成人患者,共111例(托法替布60例、乌帕替尼51例),来自23个国际中心。
  • 采用逆概率治疗加权倾向校正分析和双重稳健估计控制混杂因素。

主要发现

  • 86例(77%)使用JAK抑制剂诱导应答,25例(23%)在充分静脉激素应答后用于维持应答。
  • 中位随访31周(四分位距13至64周)。
  • 治疗开始后第3至7天,乌帕替尼应答率高于托法替布(84% vs 54%;P=0.02)。
  • 第98天应答/缓解率托法替布为45%/36%、乌帕替尼为55%/48%,第182天分别为29%/29%和39%/34%,两组可比。
  • 挽救治疗亚组分析(托法替布n=35 vs 乌帕替尼n=31)显示两组疗效结局相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Tofacitinib and upadacitinib are Janus kinase (JAK) inhibitors that are increasingly used for the treatment of acute severe ulcerative colitis (ASUC). However, comparative analyses of safety and effectiveness have not been performed for their use in this setting. METHODS: This multicenter, retrospective study enrolled hospitalized adult patients treated with tofacitinib or upadacitinib for ASUC between January 2019 and June 2024. The main outcomes were clinical response, clinical remission, and colectomy-free survival. Propensity-adjusted analyses using inverse probability treatment weighting, and double robust estimations were used to control for confounding factors. RESULTS: In total, 111 patients (60 tofacitinib, 51 upadacitinib) were enrolled across 23 international centers. JAK inhibitors were used to induce response in 86 patients (77%) and used to maintain response after adequate intravenous steroid response in 25 (23%). The median follow up was 31 weeks (interquartile range, 13-64 weeks). Between days 3 and 7 after treatment initiation, upadacitinib was associated with greater response rates (84% vs 54%; P = .02), but response/remission was comparable at day 98 (45%/36% vs 55%/48%) and day 182 (29/29% vs 39/34%). Sub-analyses for JAK inhibitor use as salvage therapy (tofacitinib [n = 35] vs upadacitinib [n = 31]) showed similar effectiveness outcomes across both groups. The probabilities of colectomy-free survival at days 98 and 182 for tofacitinib and upadacitinib were 79% and 75% and 80% and 78%, respectively, with no significant differences in the comparison of survival curves (P = .99). Treatment failure rates (where JAK inhibitors were used to maintain remission) were similar at days 98 and 182. The frequency of adverse events was comparable. CONCLUSIONS: Tofacitinib and upadacitinib appear to have similar effectiveness and safety profiles when used for the treatment of ASUC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Honap S, St-Pierre J, Colwill M, et al. Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2025. PMID: 40721074. doi:10.1016/j.cgh.2025.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。